Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

Untreated de novo (n=421) and secondary (n=189) acute myeloid leukemia (AML) patients≥60 years received intensified chemotherapy, including daunorubicin 60mg/m(2) and etoposide 100mg/m(2) during days 1, 2, 3 with cytarabine 100mg/m(2) during days 1–7, with a second induction if needed and one consol...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baer, MR, George, SL, Sanford, BL, Mrózek, K, Kolitz, JE, Moore, JO, Stone, RM, Powell, BL, Caligiuri, MA, Bloomfield, CD, Larson, RA
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3821040/
https://ncbi.nlm.nih.gov/pubmed/21321569
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2011.9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados